Investment Opportunities


RBI, Inc. is set to make a mark in the treatment of neurodegenerative diseases. By making a biomedical investment with our company, you help us continue our work on effective treatments for Alzheimer’s, ALS, and Parkinson’s disease. The following is a timeline of where this area of medical research stands, including successes and failures.

• Houlihan Lokey valuation of Regeneration Biomedical, has conservatively valued RBI in current Series A, at 33M. This includes a 92.5% chance of failure to achieve FDA approval, a 2-year delay in the timeline, and between a 25-30% discount rate.

Discover The Future

Our company is at the forefront of the biomedical research industry thanks to professionals who have had more than 30 years of medical and research experience.

Contact Us
Go to Top